We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Recently, there is a saying in the pharmaceutical industry: not all innovative drugs have a future. This saying reminds me of the lyrics - wild lilies also have spring.
Evive Biotech, a global biologics company developing novel biologic therapies, today announced the submission of its Biologics License Application (BLA) for Ryzneuta™ (also known as F-627) to the US Food & Drug Administration (FDA).
In Express Pharma’s Women’s Day Special issue, some industry observers and pharma stakeholders share insights on opportunities, challenges and focus on the women’s health segment as it continues to evolve and advance.
The presence of certain high-risk human papillomavirus (HPV) types predicts future risk for high-grade cervical cancer even among women with no cellular indications of cancer at baseline, according to a study published online Dec. 10 in Cancer....